Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.
about
Antiretroviral therapy response among HIV-2 infected patients: a systematic reviewMajor depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV diseaseEvolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response.Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection.First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaborationAssociation of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patientsCharacteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study.HIV-2 goes global: an unaddressed issue in Indian anti-retroviral programmes.Update on human immunodeficiency virus (HIV)-2 infection.Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the IeDEA West Africa Collaboration.Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort.Gag-specific CD4+ T-cell frequency is inversely correlated with proviral load and directly correlated with immune activation in infection with human immunodeficiency virus type 2 (HIV-2) but not HIV-1.Isolation of a new HIV-2 group in the US.A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.HIV-2 infection is associated with preserved GALT homeostasis and epithelial integrity despite ongoing mucosal viral replication.Mortality and survival patterns of people living with HIV-2Preservation of Lymphopoietic Potential and Virus Suppressive Capacity by CD8+ T Cells in HIV-2-Infected Controllers.Baseline characteristics, response to and outcome of antiretroviral therapy among patients with HIV-1, HIV-2 and dual infection in Burkina Faso.Effect of sex and age on outcomes among HIV-2-infected patients starting antiretroviral therapy in West Africa.Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection.Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2).
P2860
Q27003854-693E802B-C5B6-4F3E-A601-91B5989FA641Q30912292-405791D8-6E02-4015-87BB-87B5F00368FFQ33591409-98E70228-FBF9-4672-BB10-A333D26BE21FQ33809419-F7241C2D-AAFB-41AB-A686-8C14AD457500Q33891896-67574A9B-5F4C-4148-8B1E-E97B9566352BQ34387349-46F01E75-0A29-49F8-A629-F765EEEB0AD6Q34742090-30472D87-1283-427D-B453-BAB707C7918CQ34793224-2A486D9A-10A4-4D11-8398-9D4D47FDE1D4Q35008562-0A93CD1A-A599-40DE-B0B6-9FBC44F1658FQ35019924-94B2E61F-6B86-44D2-A8EE-8AB9C93B958FQ35674666-C6EBF062-ECFA-4384-900D-3C58804EE1ECQ36564668-879CECAA-6F1C-4715-B4A0-C1775A90DA51Q36898820-0FB72962-CCDE-4303-AE50-1A9E1605455EQ37001043-F46056AE-F7C7-49C9-9C9C-638B2C6C67E5Q37083896-821692C2-3D90-47F8-957D-AE58617FC86FQ37365618-650F7386-5758-4F73-9846-DAB5BA25FF59Q37859395-4F7D7D8D-8B42-478A-9C23-3A873DA2D9B3Q38780964-E6A8A7D9-4D9E-4E57-9913-36F7D0826760Q38851677-AE64EEFA-B26C-4FEA-91CD-2220DC2E0913Q39448439-1B449341-EB43-4735-B1B8-E169E79702F2Q39902009-B3AB4C9F-9451-4527-B186-813833B55DCCQ40485909-A351DF6F-14D4-460C-932A-8B3FE599D967Q42318282-343BE765-0174-41E1-9FCC-4294E331B9D3Q44990505-692DBD50-C0A4-4360-80E5-D8E5E2B7CA26Q52625498-21664914-E8AC-4737-95D8-D9BAD023381E
P2860
Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparison of viro-immunologic ...... 2-infected patients in France.
@en
Comparison of viro-immunologic ...... 2-infected patients in France.
@nl
type
label
Comparison of viro-immunologic ...... 2-infected patients in France.
@en
Comparison of viro-immunologic ...... 2-infected patients in France.
@nl
prefLabel
Comparison of viro-immunologic ...... 2-infected patients in France.
@en
Comparison of viro-immunologic ...... 2-infected patients in France.
@nl
P2093
P2860
P50
P1433
P1476
Comparison of viro-immunologic ...... 2-infected patients in France.
@en
P2093
Estibaliz Lazaro
Fabrice Bonnet
François Simon
Françoise Brun-Vezinet
P2860
P304
P356
10.1097/QAD.0B013E3282F4DDFC
P407
P577
2008-02-01T00:00:00Z